Previous 10 | Next 10 |
KalVista Pharmaceuticals ( NASDAQ: KALV ) reported clinical trial and regulatory updates for its lead drug sebetralstat, a potential oral on-demand therapy for hereditary angioedema (HAE) attacks. The company recently received additional FDA regulatory guidance for the oral disintegra...
- Phase 3 KONFIDENT clinical trial passes 50% enrollment milestone - - Topline data still expected in H2 2023 - KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, sma...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors today announced that results from the phase 2 trial evaluating the efficacy and safety of oral sebetral...
– Oral sebetralstat regimen for short-term prophylaxis to be evaluated in KONFIDENT-S – – Positive phase 1 sebetralstat data supports KONFIDENT trial expansion to Japan – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will be presenting at the SVB Securities Global Biopharma Conference (virtual) on Thu...
Summary KalVista intends to provide best-in-class therapies, both for acute on-demand and prophylaxis treatment, to fundamentally change the way HAE is treated. The backbone of the company is Sebetralstat, which is currently being investigated in a phase 3 trial for the on-demand treatm...
- Expanded role to lead business and commercial growth – - Follows $58 million financing in December 2022 led by top-tier syndicate – KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, ...
KalVista Pharmaceuticals ( NASDAQ: KALV ) is selling common shares and warrants to institutional investors in a registered direct offering to raise gross proceeds of ~$58M. The company is selling ~9.48M common shares at $6 per share and 182.47K prefunded warrants at $5.999 fo...
KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it has entered into a subscription agreement with institutional investors to sel...
KalVista Pharmaceticals press release ( NASDAQ: KALV ): Q2 GAAP EPS of -$0.90 beats by $0.16 . Cash, cash equivalents and marketable securities were $122.3 million as of October 31, 2022, compared to $166.2 million as of April 30, 2022. The decrease in the net cash and marketa...
News, Short Squeeze, Breakout and More Instantly...
KalVista Pharmaceuticals Inc. Company Name:
KALV Stock Symbol:
NASDAQ Market:
KalVista Pharmaceuticals Inc. Website:
2024-07-12 17:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary angioedema (HAE). The trial will enroll approximately 24 children aged...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the submission of a New Drug Application (NDA) for U.S. Food and Drug Administration (FDA) review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) a...